Metabolic syndrome is independently associated with improved overall survival to first-line therapy with immune checkpoint inhibitors in non-small cell lung cancer.
Bou Zerdan M, Ashok Kumar P, Barrios DM, Glidden A, Nasr D, Niforatos S, Ghelani G, Leibovitch J, Nasr S, Kc B, Ombada M, Khokhar F, Poudyal B, Bhandari J, Shahnawaz M, Graziano S, Lim SH.
Bou Zerdan M, et al. Among authors: niforatos s.
Front Oncol. 2023 May 12;13:1134824. doi: 10.3389/fonc.2023.1134824. eCollection 2023.
Front Oncol. 2023.
PMID: 37251929
Free PMC article.